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Background: Inhalation of asbestos ﬁbers can lead to adverse health effects on the lungs. This study
describes lung function proﬁles among individuals with nonmalignant asbestos-related disorders (ARDs).
Methods: The study population was from the Workers’ Compensation (Dust Diseases) Board of New
South Wales, Sydney, Australia. Lung function measurements were conducted in males with asbestosis
(n ¼ 26), diffuse pleural thickening (DPT; n ¼ 129), asbestosis and DPT (n ¼ 14), pleural plaques only
(n ¼ 160) and also apparently healthy individuals with a history of asbestos exposure (n ¼ 248). Stan-
dardized spirometric and single-breath diffusing capacity for carbon monoxide (DLCO) measurements
were used.
Results: Mean age [standard deviation (SD)] was 66.7 (10.3) years for all participants. Current and
ex-smokers among all participants comprised about 9.0% and 54.8%, respectively. Median pack-years (SD)
of smoking for ex- and current-smokers were 22.7 (19.9). Overall 222 participants (38.6%) and 139
participants (24.2%) had forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC)
measurements < 80% predicted, and 217 participants (37.7%) had FEV1/FVC results < 70%. A total of 249
individuals (43.8%) had DLco values < 80% predicted and only 75 (13.2%) had DLco/VA results < 80%
predicted. A total of 147 participants (25.6%) had peak expiratory ﬂow (PEF) measurements < 80%
predicted. The presence of ARDs lowered the lung function measurements compared to those of healthy
individuals exposed to asbestos.
Conclusion: Lung function measurement differs in individuals with different ARDs. Monitoring of lung
function among asbestos-exposed populations is a simple means of facilitating earlier interventions.
 2014, Occupational Safety and Health Research Institute. Published by Elsevier. All rights reserved.1. Introduction
Asbestos is a naturally occurring mineral ﬁber which is known
as a human carcinogen [1]. More than 100,000 people die annually
in occupational settings due to asbestos-related diseases caused by
inhalation of asbestos ﬁbers [2]. Diseases related to asbestos
exposuremostly affect the respiratory system, but in rare cases they
affect other locations such as the ovaries and larynx [1]. Reduced
lung function among individuals with a history of asbestos expo-
sure is common and has been well recognized [3e6]. Althoughmanities and Social Medicine, Col
erms of the Creative Commons At
ribution, and reproduction in any
l Safety and Health Research Institsubstantial evidence for impairment of lung function is already
described in populations exposed to asbestos, many studies have
included cohorts of asbestos-exposed workers, with fewer com-
parisons between asbestos-exposed individuals without disease
and those with asbestos-related disorders (ARDs). The use of lung
functionmeasurements to screen ARDs is still widely employed as a
primary screening tool.
Several recent reports have warned that ARDs in Asian countries
could increase in the near future [7e9] because asbestos con-
sumption has been high since the late 1980s and into the 1990s [10].lege of Medicine, Kosin University, 262 Gamcheonro, Seogu, Busan 602-702, Korea.
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
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made prior to monitoring of lung function. Nevertheless, adverse
health impacts from asbestos exposure are not well recognized in
this region. The purpose of this study was to determine the lung
function proﬁles among individuals with nonmalignant ARDs.
2. Materials and methods
2.1. Study population
We obtained data from a study population that is well-described
elsewhere [11]. In brief, the study was conducted at the Workers’
Compensation (Dust Diseases) Board of New South Wales, Sydney,
Australia. This study had approval from the Human Research Ethics
Committee of St. Vincent’s Hospital, Sydney, Australia. All partici-
pants gave their written informed consent and were not compen-
sated for their participation. Participants were diagnosed with their
respective ARDs according to the American Thoracic Society (ATS)
criteria [12]. Criteria for asbestosis included a history 25 ﬁber/mL-
years exposure to asbestos, the presence of bilateral ﬁne end-
inspiratory crackles on auscultation, and the presence of subpleural
interstitial opacities on chest radiology (usually high resolution
computer tomography scan), in the absence of other causes of
interstitial pulmonary ﬁbrosis. Criteria for the diagnosis of diffuse
pleural thickening (DPT)were involvementof>25%of the chestwall
on plain chest radiology, 8 cm  5 cm  3 cm in total on chest
computer tomography, and/or thepresenceof Blesovsky’s syndrome
[13]. Pleural plaques were diagnosed according to their presence on
chest radiograph or computer tomography scan, and included
calciﬁed and non-calciﬁed circumscribed pleural thickening.
In New South Wales, compensation for ARDs is provided by the
Dust Diseases Board (DDB) according to the Workers’ Compensa-
tion (Dust Diseases) Act 1942. Individuals with known or suspected
“dust diseases” are referred to the DDB and undergo a standardized
occupational history documenting asbestos exposure, clinical ex-
amination, lung function testing, and medical imaging as required.
Information is then reviewed by a Medical Authority consisting of
at least three appropriately qualiﬁed thoracic physicians. A diag-
nosis is reached or declined, and an assessment of disablement
made according to American Medical Association IV criteria [14].
2.2. Pulmonary function assessment
Forcedexpiratoryvolume in1 second (FEV1), forcedvital capacity
(FVC), percent ratiobetweenFEV1andFVC (FEV1/FVC), single-breath
carbon monoxide diffusing capacity (DLco) and DLco/alveolarTable 1
Characteristics of participants by asbestos-related disorder category
Characteristic All
Healthy* Asbe
Subjects included in ﬁnal analysis [n (%)] 577 (100) 248 (43.0) 26
Age [Mean (SD)] (y) 66.7 (10.3) 60.9 (10.5) 72.7
Smoking status (%)
Ex-smoker 54.8 42.3 61.5
Current smoker 9.0 11.7 11.5
Never smoker 36.2 46.0 26.9
Pack years [mean (SD)] 22.7 (19.9) 21.0 (18.2) 24.8
Body mass index, kg/m2 [n (%)]
18.5e24.9 105 (18.2) 46 (18.6) 3
25.0e29.9 294 (51.0) 117 (47.2) 17
30 175 (30.3) 83 (33.5) 6
ANOVA, analysis of variance.
* Apparently healthy with a history of asbestos exposure.
y Diffuse pleural thickening.
z For signiﬁcance testing: Chi-square tests were performed for proportions and ANOVvolume (DLco/VA), and peak expiratory ﬂow (PEF) were measured
by spirometry using the Sensormedics Vmax 22D-Spectra (Viasys
Healthcare, Conshohocken, PA, USA). During the study period, the
same equipment was used by the same trained technician. At least
three FVC manoeuvres and DLco trials were obtained for each
participant according to ATS guidelines [15,16]. The results were
expressed as absolute values and as percent of the predicted values
for FVC, FEV1, and DLco calculated on the basis of age, height, and
gender for Caucasians, using the predictive equations provided by
the European Respiratory Society 1993 update [17].
2.3. Data analysis
Descriptive statistics were performed for outcome and predictor
variables and covariates. Analysis of variance test and generalized
liner models (GLM) were used to compare means, while adjusting
for confounding factors, namely age, smoking pack-years, and body
mass index (BMI). The GLM procedure uses the method of least
squares and analyzes data within the framework of general linear
models, and in this case, we use the models not only to compare
two or more means, but also as linear regressions, to predict the
effect of a factor on an outcome variable. All comparisons were
two-sided and p < 0.05 was treated as signiﬁcant. Analyses were
performed in SAS, version 10 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Study population
Baseline characteristics of the participants in this study are
shown in Table 1. Data analyzed from the 577 males comprised the
following categories: asbestosis (n ¼ 26), DPT (n ¼ 129), asbestosis
and DPT (n ¼ 14), pleural plaques only (n ¼ 160, PPs) and appar-
ently healthy individuals formerly exposed to asbestos (n ¼ 248).
Mean age (SD) was 66.7 (10.3) years for all participants. Current and
ex-smokers among all participants comprised about 9.0% and
54.8%, respectively. Median pack-years (SD) of smoking for current
and ex-smokers were 22.7 (19.9). A total of 469 participants (81.3%)
were overweight and obese (BMI  25).
3.2. Pulmonary function measures
Pulmonary function outcomemeasures are described in Table 2.
Out of the sample population, 222 participants (38.6%) and 139
participants (24.2%) had FEV1 and FVC measures that were <80%
predicted, respectively, and 217 participants (37.7%) had FEV1/FVCAsbestos-related disorder category
stosis DPTy Asbestosis/DPT Pleural plaques pz
(4.5) 129 (22.4) 14 (2.4) 160 (27.7)
(6.7) 71.8 (6.8) 72.9 (6.7) 69.3 (8.9) <0.0001
73.6 85.7 55.0 <0.0001
5.4 0 8.1
20.9 14.3 36.9
(14.4) 23.5 (18.8) 15.9 (18.0) 24.5 (23.7) 0.0076
(11.5) 17 (13.2) 2 (14.3) 37 (23.1) 0.2027
(65.4) 69 (53.5) 10 (71.4) 81 (50.6)
(23.1) 43 (33.3) 2 (14.3) 41 (25.6)
A analyses for arithmetic means.
Table 2
Unadjusted lung function proﬁles among participants with asbestos-related disorders
Lung function measures All Asbestos-related disorder category
Healthy* Asbestosis DPTy Asbestosis/DPT Pleural plaques pz
FEV1 84.3 (19.4) 92.5 (17.2) 78.4 (14.0) 69.5 (16.4) 68.6 (11.7) 85.9 (18.4) <0.0001
FVC 92.5 (17.5) 100.2 (14.6) 81.9 (15.8) 79.4 (16.0) 71.4 (13.2) 94.7 (14.9) <0.0001
FEV1/FVC 70.7 (10.0) 72.6 (8.7) 73.6 (9.3) 67.2 (10.8) 73.9 (10.1) 69.8 (10.5) <0.0001
DLco 82.6 (20.0) 90.6 (18.9) 59.6 (14.1) 72.7 (16.6) 62.2 (17.8) 83.6 (17.7) <0.0001
DLco/VA 102.5 (20.5) 103.2 (18.6) 90.4 (23.6) 104.2 (22.5) 98.0 (25.2) 102.2 (20.4) 0.031
PEF 93.6 (22.0) 100.5 (20.3) 94.1 (19.9) 80.8 (21.7) 80.4 (19.3) 94.4 (20.4) <0.0001
ANOVA, analysis of variance; DLco, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory ﬂow;
SD, standard deviation.
Data are presented as mean (SD).
* Apparently healthy with a history of asbestos exposure.
y Diffuse pleural thickening.
z For signiﬁcance testing: ANOVA analyses for arithmetic means.
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had DLco values < 80% predicted and only 75 participants (13.2%)
had DLco/VA results < 80% predicted. A total of 147 participants
(25.6%) had PEF measures of <80% predicted (Table 2). Mean (SD)
FEV1% predicted levels in individuals with asbestosis [78.4 (14.0)],
DPT [69.5 (16.4)], asbestosis/DPT [68.6 (11.7)] and PPs [85.9 (18.4)]
were signiﬁcantly lower than the apparently healthy individuals
formerly exposed to asbestos [92.5 (17.2)] (p < 0.0001). Mean (SD)
FVC% predicted levels in individuals with asbestosis [81.9 (15.8)],
DPT [79.4 (16.0)], asbestosis/DPT [71.4 (13.2)] and PPs [94.7 (14.9)]
were signiﬁcantly lower than the apparently healthy individuals
with a history of asbestos exposure [100.2 (14.6)] (p < 0.0001).
Mean (SD) DLCO% predicted levels in participants with asbestosis
[59.6 (14.1)], DPT [72.7 (16.6)], asbestosis/DPT [62.2 (17.8)] and PPs
[83.6 (17.7)] were signiﬁcantly lower than the apparently healthy
participants formerly exposed to asbestos [90.6 (18.9)] (p< 0.0001).
Comparison of spirometry and diffusion capacity outcomes be-
tween the healthy individuals and individuals with ARDs revealed
statistically signiﬁcant differences in mean percent predicted for all
of these parameters (Table 2).
Age, smoking pack-years, and BMIwere included in GLMmodels
to adjust for their effects on the lung function proﬁles of the healthy
and ARD groups (Table 3) which was similar to the unadjusted
proﬁles reported in Table 2. The apparently healthy participants
with a history of asbestos exposure had better lung function than
thosewith ARDs, and differences across all groups were statistically
signiﬁcant (p < 0.0001, Table 3). Interestingly, when compared to
the unadjusted lung function proﬁles, controlling for the effects of
these three independent variables results in an overall reduction in
the lung function only among the healthy participants. The unad-
justed mean (SD) of FEV1, FVC, FEV1/FVC, DLco, DLco/VA, and PEFTable 3
Adjusted lung function proﬁles among participants with asbestos-related disorders
Lung function measures All
Healthy* Asbestosis
FEV1 85.6 (20.2) 90.4 (15.6) 80.8 (15.4)
FVC 94.2 (18.7) 98.8 (12.1) 83.5 (16.9)
FEV1/FVC 71.4 (11.6) 70.8 (10.2) 75.6 (9.8)
DLco 84.8 (22.3) 87.6 (16.2) 63.1 (16.5)
DLco/VA 104.6 (22.5) 101.9 (16.8) 92.1 (25.2)
PEF 95.2 (23.9) 98.2 (18.4) 96.8 (21.3)
ANOVA, analysis of variance; DLco, diffusing capacity for carbon monoxide; FEV1, forced
SD, standard deviation.
Data are presented as mean (SD); adjusted by age, smoking status, BMI.
* Apparently healthy with a history of asbestos exposure.
y Diffuse pleural thickening.
z For signiﬁcance testing: ANOVA analyses for arithmetic means.predicted values in the healthy group were 92.5 (17.2), 100.2 (14.6),
72.6 (8.7), 90.6 (18.9), 103.2 (18.6), and 100.5 (20.3), respectively,
whereas the adjusted mean (SD) of FEV1, FVC, FEV1/FVC, DLco,
DLco/VA, and PEF predicted values in the healthy group were 90.4
(15.6), 98.8 (12.1), 70.8 (10.2), 87.6 (16.2), 101.9 (16.8), and 98.2
(18.4), respectively. Of the six lung function measures, the lowest
mean values recorded were evenly distributed among the partici-
pants with asbestosis, DPT, and asbestosis/DPT.
4. Discussion
Although the best way of elimination of ARDs is simply to ban
asbestos usage, new cases of mesothelioma, the worst health effect
of asbestos exposure, continue to rise worldwide, due to the long
latency period between exposure and disease development [18,19].
Effective screening of ARDs is essential for the better management
of ARDs. Asbestos exposure is mostly associated with lung function
impairments [3e6]. Lung function has also been proven to be the
best predictor of survival of asbestos exposure workers [20].
The current study found signiﬁcant differences between ARDs
across all lung function measures, in agreement with previous
studies. The presence of pleural plaques has been signiﬁcantly
associated with respiratory impairment in some studies [21], but
not in others. Male asbestos-exposed individuals with DPT showed
lower DLCO and FVC than individuals without a history of asbestos
exposure alone, but the FEV1/FVC values were not different [22]. In
a study from India, workers exposed to asbestos had a mean FVC
<80% of the predicted value [23]. Abejie and colleagues [24] found
chrysotile exposed workers in China had signiﬁcantly reduced FVC,
FEV1, FEV1/FVC, and DLCO, and workers with asbestosis had lower
FVC and DLCO values but not FEV1/FVC values, compared toworkersAsbestos-related disorder category
DPTy Asbestosis/DPT Pleural plaques pz
72.1 (17.9) 69.5 (13.0) 86.6 (19.1) <0.0001
81.3 (17.4) 72.5 (14.3) 95.0 (15.2) <0.0001
68.9 (11.4) 75.1 (12.3) 70.7 (11.2) <0.0001
75.3 (19.1) 64.7 (18.9) 85.5 (18.4) <0.0001
105.0 (23.2) 98.4 (25.8) 103.4 (21.6) <0.0001
83.3 (24.2) 81.2 (21.4) 95.4 (21.3) <0.0001
expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory ﬂow;
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China was also reported by Wang et al. [25], who reported a sig-
niﬁcant drop in FVC and DLCO in 248 workers exposed to mainly
chrysotile.
Our ﬁndings support previous data that lung function in in-
dividuals with ARDs is signiﬁcantly lower than currently healthy
asbestos-exposed individuals. In our study, important factors
which affect lung function such as smoking history, age, and BMI
were adjusted for [26,27], but interestingly, controlling for the ef-
fects of these three independent variables did not have a large ef-
fect on lung function in those with ARDs, only on those who were
apparently healthy, possibly due to confounding by severity. It has
been known that cumulative exposure of asbestos is strongly
associated with lung function decline [28]. The lack of exposure
assessment was a limitation in the study, but unfortunately the
data was not collected.
In conclusion, occupational and/or environmental exposure to
asbestos is strongly related to an increased decline in lung function.
Our study shows signiﬁcant differences in lung function in in-
dividuals with ARDs compared to currently healthy individuals
with a history of previous exposure to asbestos. Regular monitoring
of lung function among asbestos-exposed populations is a simple
tool to facilitate earlier interventions.
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